AIRDUO RESPICLICK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AIRDUO RESPICLICK (AIRDUO RESPICLICK).
Combination of fluticasone propionate (corticosteroid) and salmeterol (long-acting beta2-adrenergic agonist); fluticasone reduces inflammation via glucocorticoid receptor activation, salmeterol relaxes bronchial smooth muscle via beta2-receptor stimulation.
| Metabolism | Fluticasone propionate is metabolized primarily via cytochrome P450 3A4 (CYP3A4) to an inactive metabolite. Salmeterol is metabolized by hydroxylation via CYP3A4. |
| Excretion | Renal elimination of salmeterol: approximately 25% of dose excreted unchanged in urine. Fluticasone furoate: primarily excreted as metabolites in feces (≥90%) following intravenous administration, with less than 5% excreted in urine. |
| Half-life | Salmeterol: terminal elimination half-life of 5.5 hours. Fluticasone furoate: terminal elimination half-life of approximately 24 hours, supporting once-daily dosing. |
| Protein binding | Salmeterol: 94–96% bound to albumin and alpha-1-acid glycoprotein. Fluticasone furoate: >99% bound to albumin. |
| Volume of Distribution | Salmeterol: Vd approximately 10 L/kg, indicating extensive tissue distribution. Fluticasone furoate: Vd approximately 4.5 L/kg, consistent with high lipophilicity and large extravascular distribution. |
| Bioavailability | Salmeterol: absolute bioavailability via inhalation approximately 25% of nominal dose reaching systemic circulation. Fluticasone furoate: absolute bioavailability via inhalation approximately 15–20%. Oral bioavailability negligible (<1%) for both due to extensive first-pass metabolism. |
| Onset of Action | Inhalation: bronchodilation onset within 30–60 minutes for salmeterol; fluticasone furoate has a slower onset of anti-inflammatory effects, typically evident after 1–2 weeks of regular use. |
| Duration of Action | Salmeterol: bronchodilation lasting 12 hours. Fluticasone furoate: anti-inflammatory effect sustained for 24 hours with once-daily dosing. |
| Molecular Weight | 521 |
Two inhalations (55 mcg/113 mcg per inhalation) twice daily via oral inhalation; maximum 2 inhalations twice daily. For patients with asthma, starting dose is one inhalation twice daily; may increase to two inhalations twice daily after 1-2 weeks if inadequate response.
| Dosage form | POWDER |
| Renal impairment | No dose adjustment required for renal impairment. Use with caution in patients with severe renal impairment due to potential for systemic corticosteroid effects. |
| Liver impairment | No specific dose adjustment guidelines available. Use with caution in patients with hepatic impairment due to potential for increased systemic exposure to fluticasone propionate. |
| Pediatric use | Not indicated for children under 12 years of age. For children 12 years and older, same dosing as adults: two inhalations (55/113 mcg) twice daily. |
| Geriatric use | No specific dose adjustment required. Use with caution due to potential for increased sensitivity to corticosteroids and higher risk of adverse effects; monitor closely. |
| 1st trimester | Insufficient human data; animal studies show no teratogenicity at clinically relevant doses. Avoid use unless benefit outweighs risk. |
| 2nd trimester | May be used if clearly needed; consider risk of fetal growth restriction due to maternal hypoxia. |
| 3rd trimester | May cause neonatal hypoglycemia and fetal bradycardia; avoid use close to delivery. |
Clinical note
Comprehensive clinical and safety monograph for AIRDUO RESPICLICK (AIRDUO RESPICLICK).
| Placental transfer | Placental transfer is expected due to molecular weight <500 Da and lipophilicity. Limited data in humans; crosses placenta in animal models. |
| Breastfeeding | Systemic absorption is minimal via inhalation; unlikely to cause adverse effects in breastfed infant. Use with caution in nursing mothers. |
■ FDA Black Box Warning
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. When treating asthma, only use as add-on therapy for patients not adequately controlled on other asthma-controller medications (e.g., low- to medium-dose inhaled corticosteroids) or whose disease severity clearly warrants initiation of treatment with both an inhaled corticosteroid and a LABA. Once asthma control is achieved and maintained, reassess patient and consider step-down therapy.
| Serious Effects |
Status asthmaticusAcute bronchospasm not requiring maintenance therapyHypersensitivity to active ingredient or excipients
| Precautions | Increased risk of asthma-related death with LABA, Corticosteroid withdrawal symptoms when switching from systemic corticosteroids, Risk of paradoxical bronchospasm, Increased risk of pneumonia in COPD patients, Cardiovascular effects (e.g., increased blood pressure, tachycardia) with beta-agonists, Hypersensitivity reactions, Hypercorticism and adrenal suppression with high doses or prolonged use |
| Food/Dietary | No significant food interactions. Grapefruit/grapefruit juice may slightly increase fluticasone levels but clinical impact is minimal. Avoid alcohol as it may worsen asthma symptoms. |
Loading safety data…
| Lactation Rating |
| L2 |
| Teratogenic Risk | Pregnancy Category C. In first trimester, limited human data; animal studies show fetal loss and skeletal abnormalities with high systemic exposure to fluticasone propionate. In second and third trimesters, risk of fetal growth restriction and maternal hyperglycemia from formoterol fumarate. Use only if potential benefit justifies risk. |
| Fetal Monitoring | Monitor maternal lung function, fetal growth via ultrasound (especially in third trimester), maternal blood pressure, blood glucose (formoterol may cause hyperglycemia), and signs of preterm labor. Consider fetal heart rate monitoring if prolonged high-dose use. |
| Fertility Effects | No human studies; animal studies show no impairment of fertility with fluticasone propionate or formoterol fumarate at clinically relevant doses. Theoretical risk from beta-agonist effects on uterine contractility. |
| Clinical Pearls | AirDuo Respiclick is a dry powder inhaler (DPI) containing fluticasone propionate (corticosteroid) and salmeterol (long-acting beta-agonist). It is contraindicated for acute bronchospasm. Rinse mouth after each use to prevent oral candidiasis. Not for use in patients with severe asthma due to increased risk of asthma-related death. Monitor for adrenal insufficiency during stress or surgery. Do not exceed 2 inhalations twice daily. |
| Patient Advice | Use exactly as prescribed; do not use more than 2 inhalations twice daily. · Rinse mouth with water after each use, do not swallow. · Do not use for sudden breathing problems; always have a rescue inhaler. · Store at room temperature (20–25°C) away from moisture. Do not wash the inhaler; keep it dry. · If you miss a dose, skip it; do not double dose. · Contact your doctor if symptoms worsen or rescue inhaler use increases. · Do not stop suddenly without medical advice. · Keep track of how many doses remain using the dose counter. |